Phase I Combination Study of Deforolimus (Ridaforolimus/MK8669) and MK0646 in Patients With Advanced Cancer.
Phase of Trial: Phase I
Latest Information Update: 04 Jun 2015
At a glance
- Drugs Dalotuzumab (Primary) ; Ridaforolimus (Primary)
- Indications Cancer; Colorectal cancer; Non-small cell lung cancer
- Focus Adverse reactions
- Sponsors Merck & Co; Merck Sharp & Dohme
- 28 Sep 2010 Planned end date changed from Feb 2011 to Nov 2011 as reported by ClinicalTrials.gov.
- 21 May 2010 Results will be presented at the American Society of Clinical Oncology Annual Meeting 2010, according to an Ariad Pharmaceuticals media release.
- 31 Mar 2010 Planned number of patients changed from 50 to 87 as reported by ClinicalTrials.gov.